Specialties
General MSK
Specialties
Orthopaedics
100 results found in 2ms
Can ChondroFiller delay joint replacement?Can ChondroFiller delay joint replacement?
An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.
Which specialist treats supraspinatus tendinopathyWhich specialist treats supraspinatus tendinopathy
Supraspinatus tendinopathy follows a treatment pathway where specialist selection depends on how long symptoms have persisted and whether the tendon is structurally intact: specialist MSK physiotherapy is the first contact for most patients, surgery becomes relevant only when conservative care fails or imaging reveals substantial structural damage.Supraspinatus tendinopathy follows a treatment pathway where specialist selection depends on how long symptoms have persisted and whether the tendon is structurally intact: specialist MSK physiotherapy is the first contact for most patients, surgery becomes relevant only when conservative care fails or imaging reveals substantial structural damage.
Ultrasound-Guided ChondroFiller for Hip Cartilage DefectsUltrasound-Guided ChondroFiller for Hip Cartilage Defects
An injectable collagen scaffold recruits the patient's own cells to repair hip cartilage defects; clinical cohorts report 70–85% achieve meaningful symptom relief at 3–5 years, though success requires absence of pre-existing moderate-to-severe osteoarthritis.An injectable collagen scaffold recruits the patient's own cells to repair hip cartilage defects; clinical cohorts report 70–85% achieve meaningful symptom relief at 3–5 years, though success requires absence of pre-existing moderate-to-severe osteoarthritis.
ChondroFiller for TMJ cartilage defectsChondroFiller for TMJ cartilage defects
ChondroFiller, an injectable collagen scaffold that recruits cartilage-forming cells, shows functional improvements in small-joint cartilage structurally similar to the TMJ, but remains an emerging, untested application for the jaw.ChondroFiller, an injectable collagen scaffold that recruits cartilage-forming cells, shows functional improvements in small-joint cartilage structurally similar to the TMJ, but remains an emerging, untested application for the jaw.
Supraspinatus tendinopathy specialists in the UKSupraspinatus tendinopathy specialists in the UK
Supraspinatus tendinopathy is degenerative, not inflammatory; anti-inflammatory treatment cannot address this, so management begins with physiotherapy-guided progressive loading to restore tendon capacity.Supraspinatus tendinopathy is degenerative, not inflammatory; anti-inflammatory treatment cannot address this, so management begins with physiotherapy-guided progressive loading to restore tendon capacity.
What ChondroFiller's CE approval means for UK patientsWhat ChondroFiller's CE approval means for UK patients
ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
Finding a ChondroFiller specialist in the UKFinding a ChondroFiller specialist in the UK
ChondroFiller provision is concentrated in London specialist centres because its Class III medical device status requires prescription import from Germany, real-time ultrasound-guided placement, and specialist MRI assessment to determine patient suitability.ChondroFiller provision is concentrated in London specialist centres because its Class III medical device status requires prescription import from Germany, real-time ultrasound-guided placement, and specialist MRI assessment to determine patient suitability.
ChondroFiller and Arthrosamid serve different knee conditionsChondroFiller and Arthrosamid serve different knee conditions
ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.
Hip osteoarthritis treatment before replacement surgeryHip osteoarthritis treatment before replacement surgery
UK clinical guidance requires documented completion of conservative care — physiotherapy, weight management, analgesia — before accepting a total hip replacement referral. Surgical timing is determined by functional impact, not imaging severity.UK clinical guidance requires documented completion of conservative care — physiotherapy, weight management, analgesia — before accepting a total hip replacement referral. Surgical timing is determined by functional impact, not imaging severity.
How long ChondroFiller results lastHow long ChondroFiller results last
ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.
100 results found in 2ms